XOMA Royalty

San Diego, United States Founded: 2015 • Age: 11 yrs Listed Acquired By XOMA Corporation
XOMA Royalty is engaged in biotech royalty aggregation activities.

About XOMA Royalty

XOMA Royalty is a Healthcare company based in San Diego (United States) founded in 2015 by John Bell, David Stojdl, and Brain Lichty, and was acquired by XOMA Corporation in June 2025. XOMA Royalty is engaged in biotech royalty aggregation activities. It operates on a Commission-Based model. XOMA Royalty has raised $172.06 million across 4 funding rounds from investors including Takeda Pharmaceuticals, Northleaf and Citadel. The company has 80 employees. XOMA Royalty has completed 1 acquisition, including Myst Therapeutics. Its chief executive, as recorded, is Sammy Farah. XOMA Royalty offers products and services including Royalty Acquisition and Royalty Portfolio. Its focus areas include Biotechnology and Royalty Aggregation. Its legal entity is XOMA Royalty Corporation. Its competitors include Moderna, BridgeBio and BeiGene; 3 of its 3 listed competitors have raised funding.

Company details

XOMA Royalty is involved in the aggregation of biotech royalties by acquiring economic rights to future milestone and royalty payments from pre-commercial clinical candidates. The company supports biotech firms with non-dilutive funding to advance drug development. An expansive portfolio of licenses is maintained, covering potential royalty and milestone payments for drug candidates developed by external partners. Operations are focused on mitigating single-asset risks through a diversified portfolio approach within the healthcare and biotechnology sectors.

  • Headquarters San Diego, United States
  • Employees 80
  • Founders John Bell, David Stojdl, Brain Lichty
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website turnstonebio.com
  • Social LinkedIn X
  • Acquired by XOMA Corporation (Jun 2025)
  • Legal Name Xoma Royalty Corporation
Key Metrics

Products & Services of XOMA Royalty

XOMA Royalty offers a comprehensive portfolio of products and services, including Royalty Acquisition and Royalty Portfolio.

Royalty Acquisition
Biotech Royalty Services

Rights to future royalties are acquired by the company.

Royalty Portfolio
Biotech Royalty Services

A portfolio of royalty licenses is managed strategically.

Funding Insights of XOMA Royalty

XOMA Royalty has successfully raised a total of $172.06M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $80 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $172.06M
  • Total Rounds 4
  • Last Round Series D β€” $80M
  • First Round $8.56M

    (Oct 2015)

  • Investors Count 17

All 4 funding rounds of XOMA Royalty with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2021$80MSeries D–PFM Health Sciences, Point72
Jan 2019$42.1MSeries C––
–
Nov 2016$41.4MSeries B–Orbimed
Oct 2015$8.56MSeries A–Versant Ventures
Valuation history

18 investors in total: 18 institutional.

Investors in XOMA Royalty

XOMA Royalty has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals, Northleaf and Citadel.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Healthcare companies are invested in by this private equity firm.
pfmhealthsciences.comSan Francisco, United States
Ridgeback Capital is focused on healthcare and life science investments.
ridgebackcap.comNew York, United States
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
versantventures.com
Venture capital fund focused on tech startups
sixtydegreecapital.comNorth York, Canada
Private fund focused on equity, secondary market, fund of funds, and multiple investments
2009northleafcapital.comToronto, Canada
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
1989orbimed.comNew York, United States
Brace Pharma Capital is focused on investing in innovative therapies.
bracepharma.comAtlanta, United States
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
fprimecapital.com
Sectoral Asset Management is focused on global healthcare investment.
2000sectoral.comMontreal, Canada
Diversified investment management is conducted by Teralys Capital.
teralyscapital.comMontreal, Canada
Premium access

Investor details for XOMA Royalty

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of XOMA Royalty

31 people are tracked at XOMA Royalty (12 in leadership, 11 in board & advisors, 8 in team); the tracked headcount is 80.

NameRoleGroup
John Bell
Co-FounderLeadership
David Stojdl
Co-FounderLeadership
Brain Lichty
Co-FounderLeadership
Sammy Farah
CEOLeadership
Catherine Barker
DirectorLeadership
Venkat Ramanan
CFOLeadership
Mike Burgess
Interim Chief Medical OfficerLeadership
Saryah Azmat
Chief Operating OfficerLeadership
Wendy Worcester
Vice President Finance And ControllerLeadership
Joseph Campisi
Senior Vice President and General CounselLeadership
Vijay Chiruvolu
Interim Chief Technology OfficerLeadership
Erica Golding
Vice President, Human ResourcesLeadership
Robert Seder
Scientifc AdvisorBoard & advisors
Patrick Machado
DirectorBoard & advisors
Adrian Hill
Scientifc AdvisorBoard & advisors
Alan Melcher
Scientifc AdvisorBoard & advisors
Bernhard Fox
Scientific AdvisorBoard & advisors
Eric Tran
Scientific AdvisorBoard & advisors
Kanya Rajangam
DirectorBoard & advisors
Jerel Davis
ChairmanBoard & advisors

11 more people are available in the full profile.

Premium access

Complete people profiles for XOMA Royalty

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by XOMA Royalty

XOMA Royalty has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Myst Therapeutics.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Developer of cell therapy for treating cancer
myst-tx.comLos Angeles, United States2019Jan 2021β€’β€’β€’β€’
Premium access

Complete acquisition details for XOMA Royalty

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of XOMA Royalty

6 dated milestones of XOMA Royalty across 10 years, from founding to its latest funding, stage changes and deals.

  1. Founded XOMA Royalty is founded.
  2. Funding First funding round of $8.6M.
  3. Acquisition Acquires Myst Therapeutics.
  4. Funding Latest funding round, Series D, of $80.0M.
  5. IPO Lists on the stock exchange (IPO).
  6. Exit Acquired by XOMA Corporation.

Competitors of XOMA Royalty

XOMA Royalty has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and BeiGene.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
modernatx.com2010Cambridge, United States$2.78B1,312
mRNA-based therapeutics for diseases including cancer and infections are developed.
bridgebio.com2015Palo Alto, United States$434.2M
Therapeutics for genetic diseases are developed through targeted interventions.
beigene.com2010Cambridge, United States$172M1,090
Targeted and immune-oncology drugs for cancer treatment are developed.
Premium access

Detailed competitors of XOMA Royalty

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of XOMA Royalty

The website of XOMA Royalty (turnstonebio.com) receives about 1.5K visits a month.

  • Monthly visits
    1.5K

    ▲ 639.7% vs previous month

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as XOMA Royalty (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Xoma Royalty

Premium access

Complete news archive for XOMA Royalty

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about XOMA Royalty

XOMA Royalty was founded in 2015.

XOMA Royalty is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Sammy Farah is the CEO of XOMA Royalty, as recorded in our data.

XOMA Royalty is a funded company, having raised a total of $172.06M across 4 funding rounds to date. The company's 1st funding round was a Series A of $8.56M, raised on Oct 2015.

XOMA Royalty has 80 employees.

XOMA Royalty is involved in the aggregation of biotech royalties by acquiring economic rights to future milestone and royalty payments from pre-commercial clinical candidates. The company supports biotech firms with non-dilutive funding to advance drug development. An expansive portfolio of licenses is maintained, covering potential royalty and milestone payments for drug candidates developed by external partners. Operations are focused on mitigating single-asset risks through a diversified portfolio approach within the healthcare and biotechnology sectors.

XOMA Royalty's top competitors include Moderna, BridgeBio and BeiGene.

XOMA Royalty offers Royalty Acquisition and Royalty Portfolio.

XOMA Royalty has made 1 acquisition, including Myst Therapeutics.

XOMA Royalty has 18 investors. Key investors include Takeda Pharmaceuticals, Northleaf, Citadel, Orbimed, and XOMA Corporation.

XOMA Royalty operates through Xoma Royalty Corporation.

Yes. XOMA Royalty was acquired by XOMA Corporation in June 2025.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available